Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
14592 | 761 | 33.9 | 69% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
176 | 3 | DIABETES CARE//ENDOCRINOLOGY & METABOLISM//TYPE 2 DIABETES | 58057 |
1415 | 2 | DIPEPTIDYL PEPTIDASE IV//CD26//AMINOPEPTIDASE | 7997 |
14592 | 1 | AMINOPEPTIDASE N//CD13//BESTATIN | 761 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | AMINOPEPTIDASE N | authKW | 1624309 | 15% | 36% | 114 |
2 | CD13 | authKW | 1335402 | 10% | 44% | 75 |
3 | BESTATIN | authKW | 996110 | 8% | 41% | 60 |
4 | UBENIMEX | authKW | 786125 | 3% | 85% | 23 |
5 | AMINOPEPTIDASE N INHIBITOR | authKW | 451387 | 2% | 75% | 15 |
6 | APN CD13 | authKW | 373458 | 1% | 85% | 11 |
7 | AMINOPEPTIDASE N APN CD13 | authKW | 339866 | 2% | 71% | 12 |
8 | PROBESTIN | authKW | 240744 | 1% | 100% | 6 |
9 | APN | authKW | 237558 | 2% | 39% | 15 |
10 | AMINOPEPTIDASE N CD13 | authKW | 232139 | 1% | 64% | 9 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Immunology | 1196 | 20% | 0% | 154 |
2 | Oncology | 1045 | 21% | 0% | 157 |
3 | Chemistry, Medicinal | 804 | 10% | 0% | 78 |
4 | Pharmacology & Pharmacy | 663 | 19% | 0% | 146 |
5 | Medicine, Research & Experimental | 583 | 11% | 0% | 86 |
6 | Hematology | 330 | 7% | 0% | 54 |
7 | Biochemistry & Molecular Biology | 315 | 21% | 0% | 157 |
8 | Cell Biology | 189 | 10% | 0% | 76 |
9 | Microbiology | 148 | 7% | 0% | 55 |
10 | Biotechnology & Applied Microbiology | 136 | 7% | 0% | 54 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | VASC BIOL MC3501 | 120372 | 0% | 100% | 3 |
2 | PEGGY CHARLES STEPHENSON OKLAHOMA CANC | 71327 | 1% | 44% | 4 |
3 | ANTICANC DRUGS KITA KU | 40124 | 0% | 100% | 1 |
4 | AUTONOMOUS MICROBIAL BIOL WARSAW | 40124 | 0% | 100% | 1 |
5 | BIOCHEM C MED BIOCHEM GENET | 40124 | 0% | 100% | 1 |
6 | BIOTECHNOL ANIM PRODUCT | 40124 | 0% | 100% | 1 |
7 | BLUSSON SPINAL CORD SURG | 40124 | 0% | 100% | 1 |
8 | BROWN FDN PREVENT HUMAN DIS | 40124 | 0% | 100% | 1 |
9 | CHIMIOKINES LEURS RECEPTEURS FONCT CEREBRA | 40124 | 0% | 100% | 1 |
10 | CNRS UMR7509 | 40124 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | JOURNAL OF ANTIBIOTICS | 7351 | 5% | 1% | 35 |
2 | INTERNATIONAL JOURNAL OF IMMUNOTHERAPY | 6883 | 1% | 2% | 9 |
3 | BIOMEDICINE & PHARMACOTHERAPY | 4870 | 3% | 1% | 22 |
4 | BIOMEDICINE | 2585 | 0% | 3% | 2 |
5 | BIOORGANIC & MEDICINAL CHEMISTRY | 2215 | 4% | 0% | 27 |
6 | JOURNAL OF CLINICAL HEMATOLOGY AND ONCOLOGY | 1603 | 0% | 4% | 1 |
7 | HUMAN LYMPHOCYTE DIFFERENTIATION | 1484 | 0% | 4% | 1 |
8 | JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS | 1310 | 1% | 1% | 4 |
9 | BIOTHERAPY | 1222 | 0% | 1% | 3 |
10 | ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY | 846 | 2% | 0% | 19 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | AMINOPEPTIDASE N | 1624309 | 15% | 36% | 114 | Search AMINOPEPTIDASE+N | Search AMINOPEPTIDASE+N |
2 | CD13 | 1335402 | 10% | 44% | 75 | Search CD13 | Search CD13 |
3 | BESTATIN | 996110 | 8% | 41% | 60 | Search BESTATIN | Search BESTATIN |
4 | UBENIMEX | 786125 | 3% | 85% | 23 | Search UBENIMEX | Search UBENIMEX |
5 | AMINOPEPTIDASE N INHIBITOR | 451387 | 2% | 75% | 15 | Search AMINOPEPTIDASE+N+INHIBITOR | Search AMINOPEPTIDASE+N+INHIBITOR |
6 | APN CD13 | 373458 | 1% | 85% | 11 | Search APN+CD13 | Search APN+CD13 |
7 | AMINOPEPTIDASE N APN CD13 | 339866 | 2% | 71% | 12 | Search AMINOPEPTIDASE+N+APN+CD13 | Search AMINOPEPTIDASE+N+APN+CD13 |
8 | PROBESTIN | 240744 | 1% | 100% | 6 | Search PROBESTIN | Search PROBESTIN |
9 | APN | 237558 | 2% | 39% | 15 | Search APN | Search APN |
10 | AMINOPEPTIDASE N CD13 | 232139 | 1% | 64% | 9 | Search AMINOPEPTIDASE+N+CD13 | Search AMINOPEPTIDASE+N+CD13 |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | BAUVOIS, B , DAUZONNE, D , (2006) AMINOPEPTIDASE-N/CD13 (EC 3.4.11.2) INHIBITORS: CHEMISTRY, BIOLOGICAL EVALUATIONS, AND THERAPEUTIC PROSPECTS.MEDICINAL RESEARCH REVIEWS. VOL. 26. ISSUE 1. P. 88-130 | 115 | 36% | 137 |
2 | MINA-OSORIO, P , (2008) THE MOONLIGHTING ENZYME CD13: OLD AND NEW FUNCTIONS TO TARGET.TRENDS IN MOLECULAR MEDICINE. VOL. 14. ISSUE 8. P. 361-371 | 63 | 59% | 121 |
3 | ZHANG, X , FANG, H , ZHANG, J , YUAN, Y , XU, W , (2011) RECENT ADVANCE IN AMINOPEPTIDASE N (APN/CD13) INHIBITOR RESEARCH.CURRENT MEDICINAL CHEMISTRY. VOL. 18. ISSUE 32. P. 5011-5021 | 37 | 93% | 10 |
4 | GULLBO, J , WICKSTROM, M , LARSSON, R , NYGREN, P , (2011) AMINOPEPTIDASE N (CD13) AS A TARGET FOR CANCER CHEMOTHERAPY.CANCER SCIENCE. VOL. 102. ISSUE 3. P. 501 -508 | 47 | 56% | 84 |
5 | GABRILOVAC, J , BRELJAK, D , CUPIC, B , AMBRIOVIC-RISTOV, A , (2005) REGULATION OF AMINOPEPTIDASE N (EC 3.4.11.2; APN; CD13) BY INTERFERON-GAMMA ON THE HL-60 CELL LINE.LIFE SCIENCES. VOL. 76. ISSUE 23. P. 2681-2697 | 44 | 83% | 14 |
6 | ZHANG, XP , XU, WF , (2008) AMINOPEPTIDASE N (APN/CD13) AS A TARGET FOR ANTI-CANCER AGENT DESIGN.CURRENT MEDICINAL CHEMISTRY. VOL. 15. ISSUE 27. P. 2850-2865 | 45 | 69% | 28 |
7 | SCORNIK, OA , BOTBOL, V , (2001) BESTATIN AS AN EXPERIMENTAL TOOL IN MAMMALS.CURRENT DRUG METABOLISM. VOL. 2. ISSUE 1. P. 67-85 | 67 | 54% | 55 |
8 | LIS, M , OBMINSKA-MRUKOWICZ, B , (2011) EFFECTS OF BESTATIN ON PHAGOCYTIC CELLS IN CYCLOPHOSPHAMIDE-TREATED MICE.PHARMACOLOGICAL REPORTS. VOL. 63. ISSUE 6. P. 1481-1490 | 30 | 91% | 3 |
9 | HOU, JN , JIN, K , LI, J , JIANG, YQ , LI, XY , WANG, XJ , HUANG, YX , ZHANG, YJ , XU, WF , (2016) LJNK, AN INDOLINE-2,3-DIONE-BASED AMINOPEPTIDASE N INHIBITOR WITH PROMISING ANTITUMOR POTENCY.ANTI-CANCER DRUGS. VOL. 27. ISSUE 6. P. 496 -507 | 22 | 92% | 1 |
10 | LIS, M , SZCZYPKA, M , SUSZKO, A , OBMINSKA-MRUKOWICZ, B , (2013) `THE EFFECTS OF BESTATIN ON HUMORAL RESPONSE TO SHEEP ERYTHROCYTES IN NON-TREATED AND CYCLOPHOSPHAMIDE-IMMUNOCOMPROMISED MICE.IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY. VOL. 35. ISSUE 1. P. 133-138 | 25 | 89% | 1 |
Classes with closest relation at Level 1 |